Atara：FDA A类会议确认重新提交tab-cel BLA的路径

Atara及其合作伙伴Pierre Fabre收到FDA指导意见，确认现有3期ALLELE试验数据可支持重新提交tabelecleucel BLA。重新提交将包含更新数据集，纳入更多患者及更长随访期。Atara在FDA获批后仍有资格获得3100万美元里程碑付款，并按净销售额收取两位数特许权使用费。

关键事实

申报时间: 2026年8月12日 20:10
事件: 其他
方向: 中性
公司: ATRAAtara Biotherapeutics, Inc
资产: tabelecleucel
来源: SEC 8-K
可信度: 有来源
里程碑付款: FDA批准后3100万美元

来源摘录

EX-99.1 2 atra-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress Productive Type A Meeting with FDA for tabelecleucel FDA guidance provided on resubmission of tabelecleucel BLA Year over Year costs and operating expenses reduction of 87% THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2026 and business updates. “This was an important quarter for Atara. We and our partners, Pierre Fabre Pharmaceuticals (PFP), had a producti

SEC 8-K